<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We attempted a combination chemotherapy with <z:chebi fb="0" ids="28680">cytarabine</z:chebi> ocfosfate (SPAC) and <z:chebi fb="0" ids="4911">etoposide</z:chebi> for <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and <z:hpo ids='HP_0011009'>acute</z:hpo> non-lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> developing after a prior history of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/ANLL) </plain></SENT>
<SENT sid="1" pm="."><plain>SPAC and <z:chebi fb="0" ids="4911">etoposide</z:chebi> were administered orally at the dose of 200 mg/day and 25 mg/day for 14 days, as standard regimen </plain></SENT>
<SENT sid="2" pm="."><plain>Two cases complete remission (CR), 4 of partial remission (PR) were obtained among 9 patients </plain></SENT>
<SENT sid="3" pm="."><plain>The plasma concentration of <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (Ara-C) reached a plateau at around 4.5 ng/ml during the treatment period from the 7th to the 14th day, and it was detectable with a gradual decrease until the 28th day in spite of the last administration of SPAC on the 14th day </plain></SENT>
<SENT sid="4" pm="."><plain>It is suggested that this combination chemotherapy is useful against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/ANLL and other resistant <z:hpo ids='HP_0001909'>leukemia</z:hpo>, especially in elderly patients who can not be treated by intensive combination chemotherapy </plain></SENT>
</text></document>